|9 Months Ended|
Sep. 30, 2018
Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:
For the three months ended September 30, 2018 and 2017, the Company had inventory write-downs of $295,000 and $319,000, respectively, and for the nine months ended September 30, 2018 and 2017, the Company had inventory write-downs of $877,000 and $1.0 million, respectively, relating primarily to product obsolescence.
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
Reference 1: http://www.xbrl.org/2003/role/presentationRef